Counting Conditions on Newborn Bloodspot Screening Panels in Australia and New Zealand
Authors:
- Natasha HeatherNatasha Heather
- Ronda F. GreavesRGRonda F. Greaves
- Kaustuv BhattacharyaKaustuv Bhattacharya
- Lawrence GreedLGLawrence Greed
- James PittJames Pitt
- Carol Wai-Kwan SiuCSCarol Wai-Kwan Siu
- Mark de HoraMark de Hora
- Ricky PriceRPRicky Price
- Enzo RanieriEREnzo Ranieri
- Tiffany WottonTWTiffany Wotton
- Dianne WebsterDianne Webster
Open Access
- 5 July 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 10 (3) , 47
Abstract
A greater number of screened conditions is often considered to equate to better screening, whereas it may be due to conditions being counted differently. This manuscript describes a harmonised Australasian approach to listing target conditions found on bloodspot screening panels. Operational definitions for target disorders and incidental findings were developed and applied to disorder lists. A gap analysis was performed between five, state-based Australian newborn screening programme disorder lists and the single national New Zealand and state-level Californian versions. Screening panels were found to be broadly similar. Gap analysis with Californian data reflected differences in jurisdictional approval (for example, haemoglobinopathies and lysosomal disorders not being recommended in Australasia). Differences amongst Australasian panels reflected varied the timeframes recommended in order to implement newly approved disorders, as well as decisions to remove previously screened disorders. A harmonised approach to disorder counting is essential to performing valid comparisons of newborn bloodspot screening panels.Keywords
This publication has 15 references indexed in Scilit:
- Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort studyThe Lancet Child & Adolescent Health, 2023
- 3‐Methylglutaconyl‐CoA hydratase deficiency: When ascertainment bias confounds a biochemical diagnosisJIMD Reports, 2022
- Method modification to reduce false positives for newborn screening of guanidinoacetate methyltransferase deficiencyMolecular Genetics and Metabolism, 2022
- The implementation of newborn screening for spinal muscular atrophy: the Australian experienceGenetics in Medicine, 2019
- The decision to discontinue screening for carnitine uptake disorder in New ZealandJournal of Inherited Metabolic Disease, 2019
- Nine years of newborn screening for classical galactosemia in the Netherlands: Effectiveness of screening methods, and identification of patients with previously unreported phenotypesMolecular Genetics and Metabolism, 2017
- Newborn Screening for Congenital Adrenal Hyperplasia in New Zealand, 1994–2013The Journal of Clinical Endocrinology & Metabolism, 2015
- Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiencyJournal of Inherited Metabolic Disease, 2013
- Naming and Counting Disorders (Conditions) Included in Newborn Screening PanelsPediatrics, 2006
- Screening Newborns for Inborn Errors of Metabolism by Tandem Mass SpectrometryNew England Journal of Medicine, 2003